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Abstract:  The association of α-amino-β-methylaminopropionic acid (BMAA) with 
elevated incidence of amyotrophic lateral sclerosis/Parkinson’s disease complex 
(ALS/PDC) was first identified on the island of Guam. BMAA has been shown to be 
produced across the cyanobacterial order and its detection has been reported in a variety of 
aquatic and terrestrial environments worldwide, suggesting that it is ubiquitous. Various  
in vivo studies on rats, mice, chicks and monkeys have shown that it can cause 
neurodegenerative symptoms such as ataxia and convulsions. Zebrafish research has also 
shown disruption to neural development after BMAA exposure. In vitro studies on mice, 
rats and leeches have shown that BMAA acts predominantly on motor neurons. Observed 
increases in the generation of reactive oxygen species (ROS) and Ca
2+ influx, coupled with 
disruption to mitochondrial activity and general neuronal death, indicate that the main 
mode of activity is via excitotoxic mechanisms. The current review pertaining to the 
neurotoxicity of BMAA clearly demonstrates its ability to adversely affect neural tissues, 
and implicates it as a potentially significant compound in the aetiology of 
neurodegenerative disease. When considering the potential adverse health effects upon 
exposure to this compound, further research to better understand the modes of toxicity of 
BMAA and the environmental exposure limits is essential. 
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1. The Cycad Hypothesis 
Medical research attention was drawn towards Guam in 1953 when it was reported that the 
incidence of an amyotrophic lateral sclerosis/Parkinson’s disease complex (ALS/PDC) within the local 
Chamorro people was 100 times higher than the rest of the world [1-3]. After failing to identify any 
clear genetic correlation to this observation, attention was turned to environmental/cultural factors that 
might be responsible [2,3]. The use of cycad (Cycas circinalis) flour to make tortillas, soups and 
dumplings by the native Chamorro people [4,5], coupled with various field reports that livestock 
developed progressive and irreversible ataxia after ingesting cycads [6], led to the suggestion that 
cycad consumption could be the cause of the human condition [5], and thus the cycad hypothesis was 
born. In 2007 a group of biostatisticians, led by Borenstein, conducted an in depth population study of 
the Chamorro people, statistically showing that eating cycads presented the highest associated risk of 
developing ALS/PDC [7]. 
2. Proving the BMAA Link 
In 1967 Vega and Bell [8] isolated a non-protein amino acid, α-amino-β-methylaminopropionic 
acid, later renamed BMAA (Figure 1), from cycad seeds. By injecting chemically synthesised BMAA 
into chicks and rats at 3–7 μmoles/g body weight for chicks, and 6–14 μmoles/g body weight for rats, 
and subsequently observing weakness, convulsions and general loss of coordination in both animals 
they determined that BMAA possessed neurotoxic properties [8,9]. 
Figure 1. The chemical structure of β-methylaminoalanine (BMAA). 
 
Despite this observation, little attention was paid to BMAA until 1987, when Spencer et al. 
correlated elevated incidence of ALS in communities in the Kii peninsula of Japan [10] and Irian Jaya 
(West New Guinea) [11] to the traditional use of cycad pulp and sap in medicinal broths and in 
concoctions used to treat wounds. They hypothesised that BMAA was the cycad component that 
caused ALS and possibly Parkinson’s and Alzheimer’s diseases in Guam and elsewhere [12]. The 
group then conducted a major experiment in which they fed BMAA (100 to 250 mg/kg) to macaques 
for up to 12 weeks and observed a variety of symptoms indicating that the animals were suffering from 
neurodegeneration [13]. This was quickly questioned by Duncan et al. [14], who suggested that more Int. J. Environ. Res. Public Health 2011, 8          
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than 80% of BMAA was removed from cycad seeds during processing, and by Garruto et al. [15] who 
calculated (based on the knowledge of the time) that the doses used were equivalent to a 70 kg man 
consuming 1500 kg of cycad flour. These claims led many to believe that BMAA could not possibly 
be the causative agent, especially when considering the report that at least 85% of the free BMAA was 
removed from the flour with a single wash, thereby making it impossible to consume toxic quantities [16]. 
In 2002, Cox and Sacks  [17] rejuvenated the idea by proposing a biomagnification process of 
BMAA accumulation involving flying foxes that fed on cycads. The flying foxes were part of the 
traditional diet of the Chamorro people, meaning that the concentrations of BMAA actually consumed 
by humans were much higher than previously thought. Monson et al. [18] compiled further evidence 
correlating increases in flying fox consumption with increases in ALS incidence, thereby providing 
support for this idea. Whilst the native species of flying foxes are now almost extinct in Guam, testing 
of dried skin samples from museum specimens revealed BMAA concentrations equivalent (per weight) 
to up to 1014 kg of processed cycad flour [19], supporting the bioaccumulation hypothesis. 
At this point in time the source of BMAA in cycads was unknown. In 2003 Cox et al. [20] revealed 
that BMAA was present in coralloid roots of cycads, but not in roots with normal morphology. It was 
already known that cyanobacteria lived in the coralloid roots of cycad plants, where they exist as 
nitrogen fixing symbionts [21]. Cyanobacteria isolated from coralloidal roots were then found to 
produce BMAA [20]. Subsequent testing of a variety of cyanobacterial species revealed that over 90% 
of all genera tested, encompassing all five sections of this phylum, produced BMAA [22,23].   
The group of Marler et al. [24] have suggested that cycad plants can produce BMAA in normal roots 
lacking symbiotic interaction. While this raises doubts over cyanobacterial involvement, they   
do suggest that inoculation with cyanobacteria may induce increased production of BMAA by the  
cycad roots.  
In 2003, studies conducted by Banack and Cox [25] showed that, within cycad plants, BMAA was 
concentrated in the seeds, which are ground up to make flour, that is then washed and used for 
cooking. Another study conducted by Murch et al. [26] detected BMAA in the brain tissues of six out 
of six Chamorro people who had died of ALS/PDC as well as one asymptomatic Chamorro individual 
(although at lower concentrations). Interestingly the same study also found BMAA at significant 
concentrations in the brain tissue of two Canadians who had died of Alzheimer’s disease (AD), 
suggesting that BMAA may play a role in various types of neurodegenerative disease [26]. These brain 
tissue samples had been fixed in paraformaldehyde prior to storage in a 15% buffered sucrose 
maintenance solution [26]. In this, and an associated study, BMAA was detected in protein 
precipitates, revealing that it can exist in an unknown peptide bound form that had not previously been 
quantified. The concentrations of this bound form were 10–240 fold higher than those of free BMAA, 
showing that the accumulated levels were much higher than was previously thought [27]. HPLC and 
mass spectrometry were used to identify and quantify BMAA in tested samples with a detection limit 
of 100 pmol [26,27]. These findings were brought into question in 2005 when Montine et al. [28] 
conducted their own study and failed to detect any free BMAA in any brain samples taken from the 
Chamorro ALS/PDC victims or US AD victims. The same research group again failed to detect free or 
protein-associated BMAA in similar post mortem brain samples in 2009 [29]. These observations led 
them to conclude that BMAA did not accumulate in brain tissues and therefore could not cause 
neurodegeneration. The tissue samples used in these studies had been flash frozen in liquid nitrogen Int. J. Environ. Res. Public Health 2011, 8          
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and stored at −80 °C, without the use of any fixative or preservative. Both groups prepared their 
samples using trichloracetic acid (TCA) protein precipitation techniques, however a different   
HPLC-fluorescence detection (HPLC-FD) method was used by Montine et al. [28] with a claimed 
detection limit of 1 pmol (100 times more sensitive than the method of Murch et al. [26]). The 
different methods used by the group of Montine et al. [28,29] have been suggested by some   
parties [30,31] to be responsible for a lack of detection, rather than an actual lack of BMAA   
presence in tested samples. The 6-Aminoquinolyl-N-hydroxysuccinimidyl carbamate method used by  
Murch et al. [26] is more stable than the other methods [32], and is the preferred method for analysis 
of amino acids [33]. Instability of the method used by Montine et al. might explain the lack   
of detection. 
In 2006 Banack et al. [4] tested various organs, including the brain and muscle samples of flying 
foxes from Guam as well as the nearby islands of Yap and Samoa, finding significant levels of BMAA 
contained in all Guamanian samples, as well as detectable levels in most samples from Yap. They also 
proposed that consumption of other cycad foraging animals, such as wild deer and boars, could 
increase BMAA ingestion in the Chamorros. A study by Pablo et al. [34] detected high concentrations 
of BMAA in 49 out of 50 postmortem brain samples from ALS and AD sufferers in North America, 
and importantly, no BMAA was detected in healthy controls. This provided further evidence that 
bioaccumulation of BMAA in neurodegenerative disease sufferers may be a global concern. 
In 2007, Banack et al. [35] employed five different detection methods to show that laboratory 
cultures of free-living marine Nostoc species produce BMAA, proving that it could be produced 
globally. The ubiquitous nature of cyanobacteria means that given the right conditions, bioaccumulation 
of BMAA could potentially occur in any of the greatly varying environments in which cyanobacteria 
are found [26]. This presumption is supported by the growing number of reports of BMAA detection in 
different environments. Bioaccumulation of BMAA has been shown in aquatic species such   
as zooplankton, fish, mussels and oysters in the Baltic Sea [36], as well as in food chains in   
South Florida [37]. BMAA has also been detected in fresh water lakes in China [38], and in desert dust 
from the Middle East [39]. The potential for bioaccumulation is supported by the in vivo uptake of 
BMAA by the aquatic macrophyte Ceratophyllum demersum in an experimental system [40], and 
bioconcentration in the zooplankton Daphnia magna [41]. 
3. Neurodegeneration is Caused by Excitotoxicity 
Excitatory amino acids (EAAs) act as neurotransmitters within the nervous system [42]. Their 
action is performed by binding to EAA receptors that are present on all nerve cells, particularly 
concentrated in the synapses. EAA receptors mediate excitatory synaptic transmission via control of 
the flow of ions, most notably Ca
2+, K
+, Na
+, Mg
2+ and Cl
− [43]. Malfunctions in this system can lead 
to neurons being damaged and fatally compromised, a process known as excitotoxicity [44]. 
Excitotoxic cell death involves prolonged depolarization of neurons, changes in intracellular calcium  
concentrations, and the activation of enzymatic and nuclear mechanisms of cell death [45]. The   
main EAA receptors are quisqualate/α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA),  
N-methyl-D-apartate (NMDA) and metabolic glutamate receptors (mGluR), all of which are activated 
by glutamate and similar substances. A review by Doble [45] explained all these concepts and Int. J. Environ. Res. Public Health 2011, 8          
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activities in great detail. The idea that excitotoxicity is a main player in neurodegenerative disease is 
supported by many studies that have shown that there is an increased level of glutamate found in the 
cerebrospinal fluid of ALS patients [46-50]. 
4. Summary of the Multiple Mechanisms of BMAA Activity 
With substantial and ever growing evidence that BMAA does play a role in the onset and 
progression of neurodegenerative diseases, the most important question is; what mode of activity does 
BMAA exert? Although BMAA had not yet been discovered, Dastur [51] fed cycad flour pancakes to 
Rhesus monkeys in 1964, observing various effects including muscle atrophy and neurodegeneration. 
Although given that cycad flour was used rather than pure BMAA, these effects may have potentially 
been influenced by other compounds present in the mixture. Immediately following the discovery of 
BMAA in 1967, Bell et al. [52,53] also conducted some very basic toxicity assays by intraperitoneally 
injecting BMAA into chicks and rats and observing the development of neurological symptoms via 
impairment of normal physical function in both cases. These findings were repeated in 1972 by Polsky 
et al. [54], with addition of mice as test subjects. In all cases all the animals suffered the same 
symptoms, namely weakness, convulsions and general lack of coordination. After this study no 
productive research using BMAA was conducted until 1987, when the revolutionary investigation of  
Spencer et al. [13] was reported. In those studies macaques were fed 100–350 mg/kg BMAA daily for 
up to thirteen weeks, resulting in corticomotoneuronal dysfunction, Parkinsonian features and behavioural 
abnormalities. The 1991 study of Rakonczay et al. [55] and 1993 study of Matsuoka et al. [56] 
produced similar findings, with BMAA injected rats displaying acute physical impairment including 
poor balance, poor coordination and convulsions. Contrary to these observations, the 1989 study of  
Perry et al. [57] fed high doses of BMAA (15.5 g/kg total, 500 mg/kg or 1000 mg/kg doses) to mice 
over an 11 week period, and observed no behavioural abnormalities during the course of the 
experiment. Analysis of brain and liver samples collected post euthanasia failed to find any evidence 
of neurochemical or neuropathological changes in the any of the sample animals [57]. Similarly, in 
2006 the group of Cruz-Aguado et al. [58] fed 28 mg/kg of BMAA, which was an exposure level they 
deemed to be an accurate environmental representation, to mice daily for 30 days. In this study they 
found no indication that neurological damage had occurred [58]. In the critical review by Karamyan 
and  Speth [31], the authors raise doubts over the methods used by Perry et al. [57] to observe 
behavioural differences, and over the doses used by Cruz-Aguado et al. [58], as possible explanations 
for their negative observations. It was also suggested by Banack et al. [59] that the mouse model may 
be a poor model to demonstrate the neurotoxicity of BMAA. It is evident that the bulk of early 
research was focused on either detecting BMAA in known (deceased) neurodegenerative sufferers, or 
observing behavioural changes in lab animals fed or injected with BMAA. While this information was 
useful it did nothing to explain the actual mechanisms of BMAA activity. 
The first mechanistic BMAA research was performed in 1988 when Weiss and Choi [60] 
discovered that BMAA only displayed activity in vitro when a physiological concentration (10 mM 
and above) of bicarbonate (HCO3
−) ions were present in the media. This discovery was soon followed 
by  Richter and Mena’s [61] observation that BMAA inhibited glutamate binding in the synaptic 
junctions of rat brains at 1 mM, but only in the presence of 20–25 mM bicarbonate ions. The Int. J. Environ. Res. Public Health 2011, 8          
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observation that effective inhibition of glutamate receptors was not achieved by BMAA at the 
extremely high level of 10 mM, independent of bicarbonate ions, supported the findings of Weiss and 
Choi [60], that HCO3
− was required for BMAA activity to occur. Follow up experiments showed that 
BMAA could bind to NMDA and non-NMDA receptors on mouse cortical neurons [62]. The 
dependence of BMAA on HCO3
− was a critical discovery as it greatly affected the results of 
experiments conducted using freshly isolated tissues where experimental reagents are generally simple 
and defined, and often did not contain HCO3
−. Using these leads Myers and Nelson [63] identified a β-
carbamate of BMAA (formed in the presence of bicarbonate), that shares structural characteristics with 
glutamic acid (glutamate, see Figure 2). This led to an explanation of a mechanism of activity, as it 
suggested that BMAA may have the ability to inhibit glutamate receptors. From this point on all 
researchers used media and/or buffers supplemented with a minimum of 20 mM bicarbonate in all 
active in vitro assays. 
Figure 2. Comparison of the structure of (A)  β-carbamate (BMAA adduct) and   
(B) glutamtic acid (glutamate). 
 
In 1990 Lindström et al. [64] gave intracerebral injections (10 or 400 μg) of BMAA to mice and 
after one week they noticed a decrease in noradrenalin (NA) levels in the hypothalamus, while there 
was no effect on dopamine or serotonin levels. No physical or behavioural effects were observed in the 
exposed animals. They suggested that the decrease in NA levels in the tissue may have been the result 
of BMAA activity on NMDA receptors, causing a release of NA. Copani et al. [65] conducted a 
thorough investigation of BMAA binding capabilities and specificities by performing in vitro assays. 
Brain slices and mixed primary cultures taken from 8-day old rats were exposed to BMAA at 1 mM in 
conjunction with various neural metabolites and antagonists of NMDA. Their results indicated that 
BMAA acts as a mixed agonist of metabotropic and NMDA receptors, and as seen in other studies, 
BMAA activity was enhanced by the presence of bicarbonate ions at 25 mM [65]. The groups of 
Rakonczay et al. [55] and Matsuoka et al. [56] performed a series of binding assays using various 
receptor antagonists after giving intracerebroventricular injections of BMAA (500 μg/day, for up to 60 
days) to rats. Their results indicated that BMAA has a mixed agonistic effect on EAA, NMDA and 
quisqualate/AMPA receptors in the synapse. In 1991–1992 Duncan’s research group conducted a 
number of experiments relating to the body’s ability to take up BMAA after oral exposure and 
transport and accumulate it in the brain. When cynomologous monkeys were orally dosed with 
BMAA, a maximum of 20% of the administered dose was metabolized, and no greater than 2.1% was 
excreted indicating that approximately 80% of orally consumed BMAA was absorbed into systemic Int. J. Environ. Res. Public Health 2011, 8          
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circulation [66]. The 1998 study by Kisby et al. [67] reported that BMAA was detected in the 
cerebrospinal fluid of orally dosed monkeys, and in the brain tissue of intraperitoneally dosed rats, 
suggesting that BMAA is able to cross the blood-brain barrier. In a later study, Duncan et al. [68] 
demonstrated in rats that, after intravenous injection, acute BMAA levels in the brain peaked at eight h 
post administration. They also demonstrated that BMAA is taken up into the brain by the large neutral 
amino acid carrier of the blood-brain barrier, which suggests that uptake may be sensitive to the same 
factors that affect neutral amino acid transport such as diet, metabolism, disease and age [69]. In 
essence this means that BMAA uptake into the brain may be increased in times of stress. 
Brownson et al. [70] assayed rat brain cells for changes in the concentration of Ca
2+ in the presence 
of BMAA (5 mM) with or without HCO3
– ions. This experiment indicated that there was a small 
increase in intracellular Ca
2+ concentration with BMAA only, but a large increase when BMAA   
and HCO3
− were added together. This further supports the belief that BMAA is dependant on HCO3
– 
as a cofactor and that the correspnding β-carbamate is the active compound. It also suggests   
another potential mechanism of activity as impairment to intracellular calcium homeostasis has   
been shown to cause disruptions in Ca
2+-dependant cascades that lead to neuronal cell death   
and neurodiseases [71,72]. 
The study of Nedeljkov et al. [73] measured the membrane input resistance of the nerve cells of the 
leech Haemopis sanguisuga after treatment with BMAA (100 μM–10 mM) and HCO3
− (20 mM).  
A significant reduction in input membrane resistance was measured, indicating that BMAA 
depolarizes the cell by increasing membrane permeability and conductance. 
In 2007, Buenz and Howe [74] intracranially injected 10 μL of 100 mM BMAA into mice that were 
then euthanized at 24 h post exposure. This study showed that BMAA caused injury to hippocampal 
neurons. They also demonstrated that BMAA increasingly caused a degree of cell death in NSC-34 
cells (a mouse derived spinal motor neuron-like cell line) as the amount of BMAA administered 
increased from 100 μM up to 1 mM. A study conducted by Lobner et al. in 2007 [75] showed that 
BMAA at concentrations as low as 10 μM can potentiate neuronal injury caused by other known 
neurotoxins such as amyloid-β and MPP
+. This observation holds great significance determining that 
very low concentrations of BMAA (orders of magnitude lower than previously thought) can potentially 
cause serious neurological damage if other factors are involved. This study also showed that BMAA 
has three-fold activity by causing excitotoxicity on NMDA and metabotropic glutamate receptor 
subtype 5 (mGluR5) receptors, and via oxidative stress. This supports the notion that BMAA may play 
a role in a variety of different neurodegenerative conditions. Rao et al. [76] concluded that low 
concentrations of BMAA (30 μM) selectively injure motor neurons via excitotoxic activation of 
AMPA/kainite receptors. They also showed that BMAA induces increases in Ca
2+ concentrations
 and 
the generation of selective reactive oxygen species (ROS) in motor neurons, with minimal effect on 
other spinal neurons. Liu et al. [77] validated the three-fold activity of BMAA described by   
Lobner et al. [75], as well as suggesting that the mechanism BMAA uses to induce oxidative stress is 
through inhibition of the cystine/glutamate antiporter system Xc
−, leading to glutathione depletion and 
oxidative stress [77]. In 2009, Nunn and Ponnusamy [78] found that 2,3-diaminopropionic acid, the 
dimethylated product of BMAA, and methylamine were formed in liver and kidney preparations from 
rats exposed to 10 mM BMAA for 24 h in vitro. It is worth noting that this product was not formed in 
brain tissues in this study. This provides evidence of yet another method of toxicity by BMAA, Int. J. Environ. Res. Public Health 2011, 8          
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although the test dose is potentially too high for the result to be environmentally significant. 
Production of methylamine is significant as it has been shown to produce a state of oxidative stress in 
rats [79]. In 2009, Karlsson et al. [80] injected radioactively labelled BMAA into frogs and mice, then 
euthanized the animals at 30 min, 1 h, 3 h, 24 h and 12 days post injection. The results showed that 
BMAA interacts/binds with melanin, particularly during its synthesis, and increasingly bioaccumulates 
in melanin and neuromelanin-containing cells over time. The authors proposed that this may   
provide a link between BMAA and the PDC symptom of pigmentary retinopathy [80]. Also in 2009,  
Lopicic et al. [81] showed that 1 mM BMAA (with 20 mM bicarbonate) causes in vitro membrane 
potential depolarization of leech nerve cells by action on non-NMDA ionotropic glutamate receptors. 
A concomitant increase in cell membrane input conductance, as well as an increase in Na
+ activity and 
a decrease in K
+ activity was noted. This indicated that, in addition to AMPA/kainite receptors, BMAA 
could initiate excitotoxicity through the activation of other non-NMDA ionotropic glutamate receptors. 
In 2009, Santucci et al. [82] injected 5–10 nM BMAA into the eyes of mice, that were then euthanized 
between 4 and 24 h post administration. Increases in retinal neuron death and the production of ROS 
were observed in this study. Also in 2009, Purdie et al. [83] exposed zebrafish embryos to BMAA at 
up to 50,000 μg/L (approx. 300 μM) for 5 days. This exposure resulted in a range of neuromuscular 
and developmental abnormalities, which could be directly related to disruptions to the glutamatergic 
signalling pathways. 
In 2010, Cucchiaroni et al. [84] found rat neurons exposed to 1 or 3 mM BMAA displayed 
increases in the production of ROS, influx of Ca
2+ and a massive release of cytochrome-c (cyt-c) into 
the cytosol. This study also demonstrated that activity was predominantly mediated via mGluR1 
receptors. These observations indicate disruption to mitochondrial activity, excitotoxicity, and 
induction of apoptosis induced by exposure to BMAA. More recently Karlsson et al. [85] injected 50 
and 200 mg/kg BMAA into neonatal rats and found that it inhibited neural development leading to 
long-term cognitive impairment and supporting the zebrafish data implicating BMAA as a 
developmental neurotoxin [83]. Most recently, Lee and McGeer [86] exposed three different neuron-
derived human cancer cell lines to BMAA. Interestingly they observed that BMAA did not cause 
damage to human neurons and concluded that the hypothesis of BMAA causing neurodegeneration in 
humans was not tenable [86]. It should however be noted, that the cell lines they used were highly 
proliferative immortalized cells that differ significantly in physiological characteristics from normal 
neurons in vivo. Summaries of both in vivo and in vitro investigations into the bioactivity of BMAA 
are presented in Tables 1 and 2 respectively. 
When reviewing BMAA literature it quickly becomes clear that there are large differences   
in opinion. When Borenstein et al. [7] proposed their correlation supporting the role of cycads 
(potential involvement of BMAA), Steele and McGeer [87] raised doubt over the statistics. When 
Duncan et al. [14] indicated that greater than 80% of BMAA is removed from cycad flour during 
processing (washing), Cheng and Banack [88] claimed that due to sampling methods, the amount of 
BMAA detected by Duncan et al. [14] has been underestimated by 7- to 30-fold and based on the 
assumption that BMAA is washed away, another candidate compound such as β-sitosterol  
β-D-glucoside (BSSG) is suggested to play the same proposed role [89]. Various studies have been 
conducted to indicate that BSSG does display neurotoxic properties [90,91]. Interestingly despite Int. J. Environ. Res. Public Health 2011, 8          
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suggestion that BMAA and BSSG are alternatives for each other, involvement of either or both, would 
support the same cycad hypothesis. 
Table 1. A chronological summary of mechanisms of BMAA activity determined by   
in vivo research. 
Route of exposure  Species 
Dose level, 
exposure time 
Research group 
and date 
Observations 
Intraperitoneal 
injections 
Rat 
Chicken 
6–14 μmoles/g 
body weight 
3–7 μmoles/g body 
weight 
Vega and Bell. 
1967 
Weakness, convulsions and 
uncoordination 
Intraperitoneal 
injections 
Rat 
Chicken 
Mouse 
6–14 μmoles/g 
body weight 
3–7 μmoles/g body 
weight 
6–14 μmoles/g 
body weight 
Polski et al. 
1972 
Weakness, convulsions and 
uncoordination 
Perorally 
Intraperitoneal 
injections 
Monkey 
Rat 
100–350 mg/kg, 
12 months 
500 mg/kg daily, 
14 days 
Kisby et al.  
1988 
BMAA can cross from gut 
to blood 
BMAA can cross the blood 
brain barrier 
Gavage Monkey 
100–350 mg/kg 
daily, up to  
10 weeks 
Spencer  
et al. 1987 
Corticomotoneuronal 
dysfunction, Parkinsonian 
features and behavioural 
abnormalities 
Gavage 
Cynomologous 
monkey 
500 mg/kg daily, 
18 days, then 
500 mg/kg 2 daily, 
28 days, then 
100mg/kg 2 daily, 
30 days 
Perry et al. 1989 
No behavioral or 
physiological effects 
observed 
Intracerebral  
injections 
Rat  
10 μg or 400 μg/ 
150–200 g rat 
Lindström  
et al. 1990 
Activation of NMDA 
receptor, release 
noradrenalin from cells 
Intracerebroventricular 
injections 
Rat  
500 μg/day  
200–250 g body 
weight,  
10–60 days 
Rakonczay  
et al. 1990 
Matsuoka  
et al. 1993 
Agonistic effects on 
NMDA, EAA and AMPA 
receptors in synapse 
Physical impairment. 
Mixed agonistic receptor 
activity 
Gavage and 
intravenous injections 
Cynomologous 
monkey, rat 
2 mg/kg gavage; 
1 mg/kg iv 
100 mg/kg gavage; 
24–400 mg/kg iv 
Duncan et al. 
1991–1992 
80% of ingested BMAA 
enters systemic circulation. 
BMAA can cross the blood 
brain barrier. 
BMAA is transported by 
neutral amino acid carriers 
so uptake can be influenced 
by diet, metabolism, 
disease and age 
Dosed feed pellets  Mouse 
28 mg/kg daily,  
30 days 
Cruz-Aguado  
et al. 2006 
No motor, cognitive or 
neuropathological effect 
observed Int. J. Environ. Res. Public Health 2011, 8          
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Table 1. Cont. 
Route of exposure  Species 
Dose level, 
exposure time 
Research group 
and date 
Observations 
Intracranial injections  Mouse  
10 μL of 100 mM, 
24 h 
Buenz and 
Howe. 2007 
Injury to hippocampal 
neurons 
Intravenous and 
subcutaneous injections 
Mouse and 
frog  
7.3 μg/kg, 30 min, 
1 h, 3 h, 24 h,  
12 days 
Karlsson  
et al. 2009 
BMAA interacts/binds 
melanin, particularly during 
synthesis, and accumulates 
in melanin and 
neuromelanin containing 
cells increasingly over time 
Ocular injections  Mouse 
5–10 nmol,  
4, 8 and 24 h 
Santucci  
et al. 2009 
Retinal neuron death and 
production of ROS 
Table 2. A chronological summary of mechanisms of BMAA activity determined by   
in vitro research. 
Experimental 
model 
Species 
Dose level, 
exposure time 
Research group 
and date 
Conclusion 
Primary cortical 
neurons 
Mouse 
3 mM, 1 h 
With and without 
10–24 mM HCO3
– 
Weiss and Choi, 
1988 
BMAA activity is dependent on 
bicarbonate at a min. of 20mM 
Primary cortical 
neurons 
Mouse 
300 μM–3 mM,  
24 h 
Weiss et al. 1989 
BMAA has activity on NMDA and  
non-NMDA receptors 
Primary cortical 
neurons 
Rat 1  mM 
Richter and 
Mena, 1989 
Inhibition of glutamate binding in 
synapse, impaired neuron function 
Chemical assay    - 
Myers and 
Nelson, 1990 
Formation of bicarbonate adduct with 
structural similarity to glutamate 
Brain slices  Rat  1 mM, acute 
Copani et al. 
1991 
BMAA acts as a mixed agonist of 
metabotropic and NMDA receptors 
Minced brain  Rat  5 mM, acute 
Brownson et al. 
2002 
Impairment of intracellular calcium ion 
homeostasis. 
Possible neuronal death. 
Effects on calcium dependent cascades 
Primary nerve 
cells 
Leech  1–10 mM, acute 
Nedeljkov et al. 
2005 
Depolarisation of cell, impaired nerve 
function. 
Membrane permeabilisation. 
Activity via glutamate receptors 
Primary 
embryonic spinal 
cord culture 
Mouse 
30–1000 μM,  
20–24 h 
Rao et al. 2006 
Increase on calcium ion concentration 
and ROS. 
Selective damage to motor neurons 
Primary mixed 
cortical cells 
Mouse 
0.1–10 mM, 24 h 
3 mM, 3 h 
(DCFDA) 
Lobner et al. 
2007 
Potentiation of other insults, makes cells 
more sensitive to other compounds. 
Increase in ROS 
NSC-34 cells  Mouse  50–1000 μM, 18 h 
Buenz and Howe 
2007 
Dose dependent death of NSC-34 cells 
Primary mixed 
cortical cell 
cultures 
Mouse  3 mM, 3 h  Liu et al. 2009 
Induction of oxidative stress is through 
inhibition of the cystine/glutamate 
antiporter system Xc
− Int. J. Environ. Res. Public Health 2011, 8          
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Table 2. Cont. 
Experimental 
model 
Species 
Dose level, 
exposure time 
Research group 
and date 
Conclusion 
Brain slices. 
Brain, liver, 
kidney 
homogenates 
Rat 
10 mM, 30 min for 
slices 
1 h for 
homogenates 
Nunn and 
Ponnusamy, 
2009 
The dimethylated product of BMAA, 
2,3-diaminopropionic acid was formed 
in liver and kidney (but not brain) 
preparations 
Nerve cells  Leech 
100–3000 μM, 
acute 
Lopicic et al. 
2009 
Action on non-NMDA ionotropic 
glutamate receptors, with a concomitant 
increase in cell membrane input 
conductance, as well as an increase in 
Na
+ activity and a decrease in K
+ 
activity. 
Possible initiation of excitotoxicity 
through activation of non-NMDA 
ionotropic glutamate receptors 
Brain slices  Rat 
100–10000 μM, 
acute 
Cucchiaroni  
et al. 2010 
BMAA activates mGluR1 receptors to 
cause neuronal degeneration 
Massive release of cyt-c into cytosol 
5. A Summary of the Mode of Action of BMAA based on the Current Literature 
The studies listed in Tables 1 and 2, while executed on vastly different test models with varying 
measurement parameters, can be combined to generate an image of the mechanisms of action of 
BMAA on a primary motor neuron as illustrated in Figure 3. After being orally consumed, 80% of 
ingested BMAA passes from the gut into the blood stream [66]. BMAA then crosses the blood-brain 
barrier via large neutral amino acid carriers [68]. The physiological concentrations of bicarbonate ions 
(10 mM and above) reacts with BMAA to form a β-carbamate [60]. In this form, BMAA can compete 
in binding various glutamate receptors, such as NMDA receptors [55,56,64,65], AMPA receptors [55,56], 
and metabotropic and ionotropic glutamate receptors [65,73,81,84] (Figure 3i). Activation of the 
various glutamate receptors leads to shifts in cellular ion concentrations resulting in increases in   
Na
+ [81] and Ca
2+ [70,76,84], and a decrease in K
+ [81] concentrations (Figure 3ii). Activation also 
causes the cell to become depolarised [73] leading to permeabilisation of the cell membrane, resulting 
in the release of noradrenalin [64] (Figure 3iii). BMAA also inhibits the cysteine/glutamate antiporter 
system Xc
− [77] (Figure 3iv), preventing the uptake of cysteine, resulting in glutathione depletion, 
which contributes to increases in oxidative stress. At the same time the system Xc
− increases the 
release of glutamate from the cell (Figure 3v), which can then bind to glutamate receptors increasing 
damage by excitotoxicity [77] (Figure 3vi). Increases in intracellular Ca
2+ concentrations disrupt 
normal mitochondrial function leading to the release of ROS into the cytoplasm, thereby contributing 
to the observed increases in ROS [75,76,82,84] (Figure 3vii). In addition, cytochrome-c is released 
from the mitochondria [84] (Figure 3viii) resulting in the induction of apoptosis. Int. J. Environ. Res. Public Health 2011, 8          
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Figure 3. Illustrative summary of the modes of action of BMAA on neurons. In vivo, 
BMAA is present as a β-carbamate (represented by the blue dots), which binds to NMDA, 
AMPA and mGlu receptors (i). Activation of glutamate receptors results in an increase in 
the levels of Na
+ and Ca
2+ in the cell, accompanied by a reduction in K
+ (ii). The cell 
becomes depolarised and the membrane becomes permeable, as illustrated by the dotted 
line, and combined with NMDA receptor activity, noradrenalin is released from the cell as 
a result (iii). The cysteine/glutamate antiporter system Xc
− is inhibited, as indicated by the 
red X (iv), leading to intracellular depletion of glutathione and an increase in ROS. This 
inhibition also causes an increase in the release of glutamate (v), which then binds to 
receptors to induce further excitotoxicity (vi). All these mechanisms combine to cause an 
increase in the generation of ROS (vii). The elevation of Ca
2+ leads to overload of the 
mitochondria resulting in a massive release of cyt-c into the cytosol (viii). 
 
6. Concluding Remarks 
Whilst the incidence of ALS-PDC on Guam was 100 times that of the world average, it peaked at 
120 cases per 100,000 people, meaning that the majority of individuals thought to be exposed to 
BMAA still escaped disease. Clearly there is still much to learn about the role(s) that BMAA plays in 
neurodegeneration. Karamyan and Speth have reviewed the available literature on the evidence for and 
against the involvement of BMAA in the development of ALS/PDC [31]. They concluded that the 
majority of studies indicate that BMAA is toxic. It is worth noting that the two studies [57,58] that 
observed no effect both utilized oral administration methods, perhaps implying reduced toxicity via 
this delivery method. One must also consider that the severe effects observed by Spencer et al. [13] 
were also obtained with oral dosing. 
When considering all the published data, it appears certain that BMAA can contribute to the onset 
and progression of neurodegenerative disease in certain susceptible individuals. It would be useful to Int. J. Environ. Res. Public Health 2011, 8          
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focus on better understanding the proposed mechanisms of BMAA activity, as well as identifying new 
as yet undescribed mechanisms that might play an important role in the overall potency of BMAA. 
Without a sound understanding of how BMAA truly works, it is impossible to predict the level of risk 
it poses with any significant degree of confidence. One question posed in the review by Karamyan and 
Speth [31] that is likely to be answered in the affirmative was “are there interactions between BMAA 
and other exogenous substances with possible synergetic toxicity?”. The potential dangers of BMAA 
acting as an accessory or combinatorial toxin, rather than being highly toxic as a sole entity, were 
indicated by Lobner et al. [75] when they demonstrated that BMAA can potentiate the activity of other 
insults. As BMAA has been shown to be co-present with other cyanotoxins, such as microcystin, 
anatoxin-a, nodularin and saxitoxin [92], this potentiation capability, may implicate BMAA as an 
important factor when considering the management strategies of these other toxins. The debate 
between BSSG and BMAA appears to be very polarized, with acceptance of one causative agent 
completely ruling out the significance of the other. It may however be more logical to consider the idea 
that as the two compounds were isolated from the same source, they are likely to be present together 
environmentally, and could therefore act in a combination, potentially far more potent than either agent 
alone, to induce neurological damage. There is little doubt that if present in sufficient concentrations, 
BMAA exerts multiple modes of neurotoxic activity, with perhaps further modes yet to be defined. 
With growing reports of its presence in varied environments it is important that research to understand 
the complete nature of BMAA toxicity continue. Equipped with a greater knowledge and 
understanding of the mechanisms of BMAA toxicity, we will be able to more accurately evaluate and 
assess the human health risks posed by exposure to this cyanotoxin.  
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